Sonnet Capex To Depreciation from 2010 to 2024

SONN Stock  USD 2.89  0.03  1.03%   
Sonnet Biotherapeutics Capex To Depreciation yearly trend continues to be very stable with very little volatility. Capex To Depreciation is likely to grow to 1.85 this year. Capex To Depreciation is the ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets. View All Fundamentals
 
Capex To Depreciation  
First Reported
2010-12-31
Previous Quarter
0.93500809
Current Value
1.85
Quarterly Volatility
2.51527142
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sonnet Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sonnet Biotherapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.3 M, Interest Expense of 2.4 M or Selling General Administrative of 2.4 M, as well as many indicators such as Price To Sales Ratio of 1.12, Dividend Yield of 0.0 or PTB Ratio of 5.12. Sonnet financial statements analysis is a perfect complement when working with Sonnet Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of Sonnet Biotherapeutics Correlation against competitors.

Latest Sonnet Biotherapeutics' Capex To Depreciation Growth Pattern

Below is the plot of the Capex To Depreciation of Sonnet Biotherapeutics Holdings over the last few years. It is the ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets. Sonnet Biotherapeutics' Capex To Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sonnet Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
Capex To Depreciation10 Years Trend
Slightly volatile
   Capex To Depreciation   
       Timeline  

Sonnet Capex To Depreciation Regression Statistics

Arithmetic Mean1.87
Geometric Mean1.05
Coefficient Of Variation134.55
Mean Deviation1.56
Median1.11
Standard Deviation2.52
Sample Variance6.33
Range9.5749
R-Value0.38
Mean Square Error5.82
R-Squared0.15
Significance0.16
Slope0.22
Total Sum of Squares88.57

Sonnet Capex To Depreciation History

2024 1.85
2022 5.85
2021 9.61
2020 0.0381
2019 1.31
2018 0.94
2017 0.71

About Sonnet Biotherapeutics Financial Statements

Sonnet Biotherapeutics investors utilize fundamental indicators, such as Capex To Depreciation, to predict how Sonnet Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Capex To Depreciation 0.94  1.85 
When determining whether Sonnet Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonnet Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonnet Biotherapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonnet Biotherapeutics Holdings Stock:
Check out the analysis of Sonnet Biotherapeutics Correlation against competitors.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.96)
Revenue Per Share
0.019
Quarterly Revenue Growth
(0.50)
Return On Assets
(0.97)
Return On Equity
(2.65)
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.